Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Durham, E. Jazrawi, J. A. Rhodes, C. Williams, I. Kilty, P. Barnes, K. F. Chung, I. Adcock (London, United Kingdom; Cambridge, United States Of America). The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway. Eur Respir J 2014; 44: Suppl. 58, 3332

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Blockade of TSLP pathway alters asthma biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Leukotrienes pathway are involved in the anti-inflammatory effects aerobic exercise on asthma Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013 The anti-inflammatory effects of aerobic exercise in asthma is mediated by purinergic signaling Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016 Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 LATE-BREAKING ABSTRACT: Morin attenuates ovalbumin-induced airway inflammation by modulating oxidative stress-responsive MAPK signaling Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Anti-inflammatory effects of resveratrol analogues in cellular models of airway inflammation Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Glucocorticoid-induced transcriptional regulators in human airway cells and airways Source: International Congress 2016 – Studies in airway cell biology Year: 2016 New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014